Abiopharma

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

Novanta - Novanta Inc. Announces Pricing of $550,000,000 Tangible Equity Units Offering

Novanta Inc. Announces Pricing of $550,000,000 Tangible Equity Units Offering